Susmita Roy
Good morning, everyone. My name is Susmita Roy. I’m an associate on the JPMorgan Healthcare Investment Banking team. On behalf of JPMorgan, thank you all for attending the Healthcare Conference. And I’m thrilled and honored to introduce Zevra Therapeutics for their company presentation today.
A little bit about Zevra before we get started. Zevra Therapeutics is a commercial-stage company with a unique opportunity to impact people living with rare diseases. The company is in growth mode, with operating runway to execute on its commercial and development priorities.
Zevra is commercializing its lead product, MIPLYFFA, in the U.S. for Niemann-Pick disease type C. In addition, the company has an MAA under review by the EMA, is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs.
Zevra has multiple revenue sources with net revenue generation of $72.3 million in the first 9 months of last year and exited Q3 with a strong cash position of $230.4 million.
We are delighted to welcome their President and CEO, Neil McFarlane, to the podium to tell us more. Thank you, Neil. And I’ll turn it over to him. Please note that Q&A will be afterwards. And if you have a question in the audience, please wait for the mic. Thank you so much.
Neil McFarlane
President, CEO & Director
Thank you, Susmita, and thank you, JPMorgan, for allowing us the opportunity to present this week. I realize it’s been a long week. And for all of you in the room, thank you for coming here on the last day of the conference.
